On December 9, 2025, WixBio successfully delivered a shipment of bivalent inactivated avian influenza (H5+H9) vaccine to a customer in Vietnam. The shipment consisted of products in 250 mL and 500 mL packaging, and it filled one standard refrigerated container, which was dispatched via sea freight.
This delivery represents a routine supply batch carefully organized by WixBio in accordance with Vietnamese market disease control requirements and the customer’s order schedule. Subtypes H5 and H9 of the avian influenza virus remain endemic in Southeast Asia and continue to pose a persistent threat to the poultry industry. The WixBio H5+H9 inactivated vaccine incorporates antigens matched to locally circulating field strains, providing effective immunogenicity and protective efficacy, and has gained broad acceptance in the Vietnamese market.
To maintain product quality and stability during long-distance sea transport, the entire shipment was transported in a professional refrigerated container with temperature strictly controlled within the 2–8 °C range. Real-time temperature monitoring and recording devices were employed, enabling full traceability of temperature conditions from the manufacturing facility to the destination port, thereby ensuring optimal vaccine potency and efficacy.
This full-container sea shipment demonstrates WixBio’s established capabilities in managing large-scale international logistics and underscores the company’s ongoing commitment to the strategically important Vietnamese market through efficient and reliable service.
WixBio stated that it will continue to leverage its stable production capacity, precise strain-matching processes, and dependable global cold-chain logistics network to supply high-quality, timely animal health vaccines to customers worldwide, including Vietnam, thereby supporting the sustainable development of the global livestock industry.
